期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

三阴性乳腺癌分子特征与潜在治疗靶点 被引量：2

原文传递
导出
摘要 乳腺癌是一种异质性很高的肿瘤。其中三阴性乳腺癌（triple-negative breast cancer,TNBC）占浸润性乳腺癌的10%~20%[1]。TNBC侵袭力强,远处转移风险大,预后差。由于不表达雌激素受体（estrogen-receptor,ER）、孕激素受体（progesterone-receptor,PR）和人表皮生长因子受2（human epidermal growth factor receptor2,HER2）,内分泌治疗及抗HER2分子靶向治疗无效。目前,有效的全身治疗措施只有细胞毒性化疗。因此,
作者 尉承泽 郝晓鹏
机构地区 军事医学科学院附属医院
出处 《中国实用外科杂志》 CSCD 北大核心 2015年第7期780-783,共4页 Chinese Journal of Practical Surgery
关键词 三阴性乳腺癌 分子特征 潜在靶点 TNBC molecular feature potential targets
分类号 R6 [医药卫生—外科学]
  • 相关文献

参考文献32

  • 1Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer [ J ]. N Engl J Med, 2010,363(20): 1938-1948.
  • 2Lehmann BI), Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selec-tion of targeted therapies [J]. J Clin Invest, 2011,121 (7):2750-2767.
  • 3Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) poly-merase inhibitor olaparib in patients with BRCA1 or BRCA2 muta-tions and advanced breast cancer: a proof-of-concept trial[J]. Lancet, 2010,376(9737):235-244.
  • 4Gelmon KA, Tischkowitz M, Mackay H, et al. olaparib in pa- tients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J]. Lancet On- col, 2011,12(9):852-861.
  • 5Dent RA, Lindeman GJ, Clemons M, et al.Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or seeond-line treatment of patients with metastatie triple-nega- tive breast cancer[J]. Breast Cancer Res, 2013,15(5):R88.
  • 6Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparih (ABT888) and temozolomide for meta- static breast cancer[J]. J Clin Oncol, 2010,28:Abstr 1019.
  • 7Gruvberger-Saal SK, Bendahl PO, Saal LH, et al. Estrogen re- ceptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma [J]. Clin Cancer Res, 2007, 13(7): 1987-1994.
  • 8Pelekanou V, Notas G, Kampa M, et al. ER- α 36, a new variant of the ER-α is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines[J]. Steroids, 2012,77(10):928-934.
  • 9Thomas P, Pang Y, Filardo E J, et al. Identity of an estrogen mem-brane receptor coupled to a G protein in human breast cancer cells[J]. Endocrinology, 2005, 146(2):624-632.
  • 10Campagnali C, Pasanisi P, Castellano I, et al. Postmenopausal breast cancer, androgens, and aromatase inhibitors [J]. Breast Cancer Res Treat, 2013, 139(1):1-11.

同被引文献18

引证文献2

二级引证文献25

中国实用外科杂志
2015年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部